



ATTORNEY'S DOCKET NUMBER: 2002850-0009 (S98-161 US CIP II)

#17
Amst. C
attach
3/12/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fount *et al.*
Serial No.: 09/728,720
Filed: December 1, 2000
For: PREVENTION AND TREATMENT OF HCV INFECTION EMPLOYING
ANTIBODIES DIRECTED AGAINST CONFORMATIONAL EPITOPES

Examiner: Wortman, D.
Art Unit: 1648

Assistant Commissioner for Patents
Washington, DC 20231

I hereby certify that this correspondence is being
deposited with the United States Postal Service as first
class mail in an envelope addressed to: Assistant
Commissioner For Patents, Washington, D.C. 20231
on February 10, 2003
Amst. C

Sir:

RESPONSE TO OFFICE ACTION UNDER 37 CFR § 1.111

In reply to the Examiner's Action that was mailed in the above-referenced case on
September 10, 2002, Applicant submits the following Amendment and Remarks.

RECEIVED
FEB 25 2003
TECH CENTER 1600/2600

Amendment

Kindly amend the application as follows. The changes made are illustrated with
underlining (added text) and brackets (deleted text) in Appendix A (Version with Markings to
Show Changes Made).

In the Specification:

Please replace the paragraph beginning at page 6, line 14, with the following rewritten
paragraph.

One aspect of the present invention provides monoclonal antibodies, including human
monoclonal antibodies, which bind to the dominant HCV types in major geographical areas. The
dissociation constants for these antibodies for their epitopes ranges from less than 10^{-7} M to less

Amst. C